Effect of blueberry on type 2 Diabetic Nephropathy

Phase 1

Completed

• Conditions: Diabetic Nephropathy.; Non-insulin-dependent diabetes mellitus with renal complications

• Registration Number: IRCT2015040712438N12
• Lead Sponsor: Barij Essence Company

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 22 February 2018

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 70

Inclusion Criteria

inclusion criteria: patients 35 to 70 years old receiving reducer blood glucose drug and dietary recommendations for 3 to 5 years with type II diabetes. That HbA1c is 9-7%. LDL-cholesterol less than 130 and triglycerides less than 300. with 0 and 1Stage of diabetic nephropathy that do not use fat-lowering drugs.
Exclusion criteria: liver disease, allergies to plants used in the clinical trial, changing the dose of drug during the study.

Exclusion Criteria

Not provided

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
HbA1C. Timepoint: Baseline and End-of-trial. Method of measurement: percent of glycosylated hemoglobin.;Insulin. Timepoint: Baseline and End-of-trial. Method of measurement: blood sample.;Lipid profile. Timepoint: Baseline and End-of-trial. Method of measurement: blood sample.;Fasting plasma glucose. Timepoint: Baseline and End-of-trial. Method of measurement: blood sample.;TAC. Timepoint: Baseline and End-of-trial. Method of measurement: blood sample.;ALT,AST. Timepoint: Baseline and End-of-trial. Method of measurement: blood sample.;BUN. Timepoint: Baseline and End-of-trial. Method of measurement: urine sample.;Creatinin. Timepoint: Baseline and End-of-trial. Method of measurement: urine sample.;PRO. Timepoint: Baseline and End-of-trial. Method of measurement: urine sample.